tiprankstipranks
Trending News
More News >

InhaleRx Advances Drug Development with Strategic Funding and Expanded Trials

Story Highlights
  • InhaleRx Limited is developing inhaled medications for cancer pain and panic disorder.
  • The company secured $38.5 million funding to accelerate drug trials and manufacturing.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
InhaleRx Advances Drug Development with Strategic Funding and Expanded Trials

Confident Investing Starts Here:

InhaleRx Limited ( (AU:IRX) ) has shared an announcement.

InhaleRx Limited has announced significant progress in its drug development efforts, supported by a $38.5 million funding agreement with Clendon Biotech Capital Pty Ltd. This funding will accelerate the development of IRX-211 and IRX-616a through to Phase 3 readiness, potentially expediting their path to market. The company has expanded the scope of its clinical trials and completed necessary adjustments for trial drug manufacturing, positioning itself to meet FDA requirements and enhance its market positioning.

More about InhaleRx Limited

InhaleRx Limited is an Australian drug development company focused on creating novel inhaled medications. The company is currently developing two drugs: IRX-211 for breakthrough cancer pain and IRX-616a for panic disorder. Their market focus includes advancing these inhaled cannabinoid medications through clinical trials with the goal of obtaining New Drug Approval from the US FDA.

YTD Price Performance: -28.57%

Average Trading Volume: 175,783

Technical Sentiment Signal: Strong Buy

Current Market Cap: A$5.34M

Find detailed analytics on IRX stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App